Integrative Molecular Phenotyping
INTEGRATIVE MOLECULAR
PHENOTYPING
WHEELOCK LABORATORY
DEPARTMENT OF MEDICAL
BIOCHEMISTRY AND BIOPHYSICS
WHEELOCK LABORATORY
DEPARTMENT OF MEDICAL
BIOCHEMISTRY AND BIOPHYSICS
WHEELOCK LABORATORY
DEPARTMENT OF MEDICAL
BIOCHEMISTRY AND BIOPHYSICS
WHEELOCK LABORATORY
DEPARTMENT OF MEDICAL
BIOCHEMISTRY AND BIOPHYSICS
WHEELOCK LABORATORY
DEPARTMENT OF MEDICAL
BIOCHEMISTRY AND BIOPHYSICS
WHEELOCK LABORATORY

KI News

Updated: 52 min 45 sec ago

KI's research impact top rated in research barometer

Tue, 18/07/2017 - 15:12
KI’s research is at the leading edge of impact according to the Swedish Research Council’s (SRC) Research Barometer for 2017 with the highest proportion of highly cited publications compared to other universities and colleges in Sweden. The SRC’s Research Barometer provides an overview of the state of Swedish research through some thirty indicators including financial resources, research staff and results generated by way of research publications and citation impact. This year’s barometer shows KI to have had the highest citation impact for scientific articles published during the period of 2013-2015 with the number of highly cited publications rising from 12 percent in 2008-2010 to 14 percent in 2013-2015.

Fewer infections in mechanical heart valves

Tue, 18/07/2017 - 10:21
Infections in surgically implanted heart valves are more common in patients who have been given a biological prosthetic valve than in those with a mechanical one, a study from Karolinska Institutet published today in the journal Circulation shows. Some 1,500 people undergo aortic valve replacement every year in Sweden, about 75 per cent of whom receive a biological valve (from a pig or calf), the remainder a mechanical one. A complication that carries a high fatality risk is prosthetic valve endocarditis, which occurs when the new valve is infected by bacteria. Until now, there have been no figures on whether the infection frequency differs between the two valve types. It has also been unknown how common infections in an artificial heart valve are. The present study included over 26,500 patients who received a prosthetic heart valve between 1995 and 2012, 940 of whom developed prosthetic valve endocarditis. The risk of infection in the artificial valve was about 50 per cent higher with a biological prosthesis than with a mechanical. The follow-up time was up to 18 years. “We hadn’t expected this large difference,” says Natalie Glaser, doctoral student at Karolinska Institutet’s Department of Molecular Medicine and Surgery. “Our results are important as they tell us more about complications following the surgical replacement of aortic valves.” The current European cardiology guidelines state that there is no difference in the incidence of infection between the two types of implant. Dr Glaser argues that this could be because former studies were too small to reveal any difference and were done on patients who were operated on decades ago.  The present study has also provided updated figures on the commonality of the complication, which affected a total of around 0.5 per cent of patients per year. It also shows that the fatality rate was as high as 16 per cent within a month of diagnosed infection and 50 per cent within five years. “The choice of valve prosthesis is very much decided by the patient’s age,” says principal investigator Ulrik Sartipy, heart surgeon at Karolinska University Hospital and docent at Karolinska Institutet’s Department of Molecular Medicine and Surgery. “Biological valves are usually used for older patients for medical reasons, partly because such valves do not require life-long treatment with anticoagulants. In our study, those who had received biological valves were on average 13 years older than those who were given mechanical ones, but this we’ve compensated for in our comparison.” The study was financed with grants from several bodies, including the Swedish Heart and Lung Foundation, the Mats Kleberg Foundation and the Magnus Bergvall Foundation. Martin Holzmann has reported that he receives a consultancy fee from Actelion and Pfizer. Publication Prosthetic valve endocarditis after surgical aortic valve replacement Natalie Glaser, Veronica Jackson, Martin Holzmann, Anders Franco-Cereceda and Ulrik Sartipy Circulation, online 17 July 2017, doi.org/10.1161/CIRCULATIONAHA.117.028783

Multimillion grant to KI researcher from AFA Försäkring

Mon, 17/07/2017 - 11:27
Jenny Selander, researcher at the Institute of Environmental Medicine (IMM), is to receive SEK 8 million from AFA Försäkring for research on how physical and chemical work environment risks affect the risk of developing cardiac and vascular diseases. Earlier studies indicate that exposure to physical and chemical work environment factors can elevate the risk of cardiac and vascular disease. Few studies, however, have focused on the impact when people are exposed to more than one environmental risk of heart and vascular disease in women in particular, or taken health and socioeconomic status in early life into consideration.  The project “Cardiac diseases in people of working age – a unified approach to determine the significance of the physical and chemical work environment” studies concurrent effects, gender-specific differences in risk and individual risk factors. Examples of the kind of work environment risk focused on include noise, air pollution, vibrations, and physical and strenuous work. The project is expected to contribute to explaining the relationship between physical and chemical work environment factors and the risk of cardiac and vascular disease. It is hoped that it will also lead to possibilities to design better preventive work. AFA Försäkring is making grants totalling SEK 50 million to six new research projects within the framework of an R&D programme focusing on research for a working life without cardiac and vascular diseases.

Research is the key to a better mental health among young people

Thu, 13/07/2017 - 14:36
Universities have an important role to play in combating the increase in mental ill-health among children and adolescents. More resources should be devoted to research in this field. These are the views of many of the participants at the seminar that KI organised in Almedalen. “The incidence of self-reported mental ill-health among boys and girls has doubled over the past 30 years. In addition, the suicide rate is not decreasing among young people as it is in all the other age groups”, said Magnus Jägerskog, Secretary General of Bris, Children’s Rights in Society. He presented a new report on mental ill-health among children, produced in collaboration with Sven Bremberg, researcher at the Department of Public Health, Karolinska Institutet. However, the cause of this increase in mental ill-health among children is unclear, with more research needed in order to find answers. Magnus Jägerskog argued that society has fallen short, and continues to fall short, when it comes to supporting children and adolescents. “According to the UN Convention on the Rights of the Child, which has now also become law, children have a right to have their voices heard in matters which concern them. But when children describe their perceptions of healthcare, we see a number of problems”, he said. He highlighted several proposed measures that he believed would require broad political reforms. Examples included equal care for children throughout the country, investments in jobs for young people and investments in training in child and adolescent psychiatry. Bris also collected a petition containing 10,000 names under the heading of #psykbryt, demanding: Equal care in all county councils. More funding for research into mental ill-health. That every case of child suicide be investigated. What can we do to improve children’s mental health? Danuta Wasserman is a professor in the Department of Public Health, KI, and has extensive experience of working with suicide prevention. She presented a method which her research group had evaluated in partnership with researchers from a range of other European countries. “Our research indicates that by helping people to help themselves, you can reduce the rate of attempted suicide by 50 per cent and the incidence of depression by 30 per cent among young people”, she said.  Pupils are able to take part in interventions such as a supervised role play in which they can explore their feelings and learn coping strategies. She quoted one participant: “This is the first time in my life that my friend has said he has also been suffering from poor mental health and I have now realised that other people can feel as bad as I have”. “This is the first time in my life that my friend has said he has also been suffering from poor mental health. The method is now being introduced in Stockholm County in order to improve mental health and reduce the number of suicides and attempted suicides among school pupils. Danuta Wasserman also took the opportunity to provide some general advice on how to improve your mental health: sleep, exercise, read books and watch films.  “This is really nothing new, this is something even my grandmother knew. But it bears repeating. Schools and society as a whole need to embrace these simple suggestions”, she said. Another KI researcher who is focusing on mental ill-health is Emily Holmes, a professor in the Department of Clinical Neuroscience. She spoke about her research into post-traumatic stress disorder (PTSD), a condition that can emerge following severe traumatic experiences, for example war. People with PTSD often experience intrusive memories, known as flashbacks, in which they involuntarily relive moments from these experiences. “We have found that the computer game Tetris, combined with other behavioural psychology interventions, can reduce the incidence of flashbacks”, she said. A small study has been carried out among young refugees who have recently arrived in Sweden. Emily Holmes presented figures that indicated mental ill-health accounts for more than 15 per cent of the total burden of disease in the West, which is greater than all forms of cancer combined. However, barely two per cent of the research budget is spent on mental ill-health in the EU.  “We need research in order to evaluate the methods we use today, but also to find new treatment methods. Children and adolescents have their whole lives ahead of them; we have the chance to make a difference!  Children and adolescents have their whole lives ahead of them; we have the chance to make a difference!  The subsequent debate also featured Ida Höckerstrand and Sofie Hallberg, the instigators of Ångestpodden [the Anxiety Podcast], Mikael Dahlqvist, Social Democrat politician and member of the Riksdag’s Committee on Health and Welfare, and KI’s Acting Vice-Chancellor Karin Dahlman-Wright. The moderator Carl Johan Sundberg asked: How can we reach out to young people? “We started Ångestpodden because we felt that it was needed. We think that our podcast has become popular because we speak the same language as young people. It is important to talk with young people, rather than about them. We give them a voice”, said Sofie Hallberg. Ångestpodden has over 30,000 listeners each month. “Many of the young people who contact us are suffering, but don’t have anyone to talk to. They don’t know where to turn. That’s not how it should be”, said Ida Höckerstrand. She argued that it would be interesting to see research that investigated the link between mental ill-health and the fact that many young people are currently living a large part of their lives on social media. Who is responsible for the issue of mental ill-health? “The Swedish Government is responsible for ensuring that Sweden complies with the Convention on the Rights of the Child”, said Magnus Jägerskog. Mikael Dahlqvist confirmed that this is an important issue. “This is a serious situation we are faced with. Swedish municipalities and county councils have initiated a number of projects in this area”, he said. Karin Dahlman-Wright, Acting Vice-Chancellor of KI, pointed out that health services have responsibility for providing healthcare, but that universities have a responsibility to disseminate existing knowledge and ensure that society benefits from research.  “We also have to test and evaluate methods – and turn back if need be. Researchers also need to determine what problems need solving. What can be more important than ensuring that our children and adolescents are well”, she said. Text and photo: Cecilia Odlind

New potential treatment for aggressive types of childhood cancer

Tue, 11/07/2017 - 08:01
A combination of substances that impacts chemical modifications in the DNA of tumours and triggers the tumours to differentiate into harmless nerve cells could represent a new method of treating aggressive forms of neuroblastoma. The new method has been proposed by researchers at Karolinska Institutet, after studies using mice showed that the combination treatment resulted in a significant suppression in tumour growth. The study, published in PNAS, also questions a hypothesis within the research field that could result in potentially harmful wrong treatment of children with neuroblastoma. Neuroblastoma affects the peripheral nervous system in children and is a tumour disease with different facets. A number of these tumours disappear naturally and others respond well to the treatment available. There are however some types of neuroblastoma that are very aggressive and, in many cases, do not respond to treatment. Mortality among these high-risk patients is high and there is therefore a substantial requirement for new and efficient methods of treatment. Significant suppression in tumour growth During the study, the researchers treated mice with the substance AZA, which blocks and eliminates methyl groups from the DNA of cancer cells, aiming to activate genes that fight the origins of neuroblastoma. AZA was then combined with treatment with retinoic acid (RA), a substance that has the capacity to make certain tumour cells differentiate, mature, into harmless nerve cells. Neither AZA nor RA could individually suppress the growth of high-risk tumours, but the combination treatment resulted in a significant suppression in tumour growth in the mice. The treatment induced expression of a factor called HIF2α, why the researchers also tested a combination with a HIF2α inhibitor. Such inhibitors have been proposed as an alternative treatment for neuroblastoma as the HIF2α protein has previously been described as being coupled to more aggressive forms of neuroblastoma. HIF2α inhibitor are currently being subject to clinical trials for treatment of other tumour diseases. “Interestingly, it emerged that the effect of our combination treatment with AZA and RA was, in fact, counteracted by the HIF2α inhibitor. Moreover, analyses of large volumes of patient data show that HIF2α is not coupled to aggressive types of neuroblastoma, but can be linked to a lower risk and improved survival for patients,” explains Johan Holmberg, researcher at the Ludwig Institute for Cancer Research and the Department of Cell and Molecular Biology at Karolinska Institutet. Potentially harmful wrong treatment with HIF2α The role played by the HIF2α inhibitors requires further study before they can be used to treat neuroblastoma patients,” confirm the researchers. “In addition to demonstrating the effect of a new potential combination treatment, our study questions a hypothesis that may result in potentially harmful wrong treatment of children with neuroblastoma. The study could therefore be of importance for future clinical applications,” says Johan Holmberg. The research has been financed by StratCan, the Swedish Cancer Society, the Swedish Childhood Cancer Foundation, the Swedish Research Council, the Ludwig Institute for Cancer Research and the Knut and Alice Wallenberg Foundation. Publication: “Combined epigenetic and differentiation based treatment inhibits neuroblastoma tumor growth and links HIF2α to tumor suppression”. Isabelle Westerlund, Yao Shi, Konstantinos Toskas, Stuart M Fell, Shuijie Li, Olga Surova, Erik Södersten, Per Kogner, Ulrika Nyman, Susanne Schlisio & Johan Holmberg. Proceedings of the National Academy of Sciences (PNAS), online 10 July 2017. For more information, please contact: Johan Holmberg, researcher The Department of Cell and Molecular Biology, Karolinska Institutet The Ludwig Institute of Cancer Research Tel: +46 (0)72-221 27 02 Email: Johan.Holmberg@ki.se

New tool demonstrates differences in human immune systems

Tue, 11/07/2017 - 08:00
Immune system function varies significantly between individuals, and up to now there has been no effective means of measuring and describing these differences. Now, researchers at Karolinska Institutet have shown that white blood cell composition is unique in individuals, and that the composition of these cells may predict immune system response to various forms of stimulation. The study, which is published in PNAS, paves the way for more individualised treatment of diseases involving the immune system, e.g. autoimmune disorders, allergies and various forms of cancer. The human immune system comprises a complex network of different white blood cells, which coordinate their efforts in order to combat different external and internal threats. This network varies widely between different individuals, but the differences have been difficult to measure and understand. Together with colleagues at the Massachusetts Institute of Technology (MIT) and Stanford University in the USA, researchers at Karolinska Institutet and the Science for Life Laboratory (SciLifeLab) have developed a tool for measuring the unique composition of white blood cells in individuals. Researchers have also found that the test may predict how individuals will respond to a given treatment, e.g. individual response to an influenza vaccine. Measuring the individual’s “immunotypes” “By measuring all populations of white blood cells in the blood at the same time, we can describe the composition of an individual’s immune system and show that this is unique for the individual. We call this measure, the individual’s “immunotype”. We have also found that this immunotype makes the complex immune system more understandable and predictable,” says Petter Brodin, physician and researcher at SciLifeLab and the Department of Medicine, Solna, at Karolinska Institutet. A human immunotype is not constant, but varies over time in response to external factors. In previous studies, Petter Brodin and his research colleagues have shown that in humans individual differences in immune defence can be attributed primarily to the many different environmental factors unique to each individual, e.g. diet, infections, vaccines and microflora. Blood samples from 1,500 individuals In the study in question, the researchers analysed blood samples from approximately 1,500 healthy individuals and tested in vitro how their white blood cells respond to different stimuli. They have also vaccinated individuals against influenza and studied which antibody protection the individuals developed thereafter. It transpired that all different types of stimulation could be predicted based on the individual’s immunotype, which was surprising – according to Petter Brodin. "Our technique can be scaled up, and my hope is that eventually it will be used clinically to predict those individuals who may benefit from a particular immunological treatment or a certain vaccine. The technique may also contribute to more individualised drugs to treat autoimmune disease and allergies, as well as immunotherapy to treat cancer, which can be adapted based on the individual’s immune response,” says Petter Brodin. The study was financed by the National Institute for Health (NIH), the Ragon Institute of MGH, MIT and Harvard, the National Science Foundation, the European Research Council (ERC starting grant), the Swedish Research Council, the Swedish Society for Medical Research, the Swedish Cancer Society and Karolinska Institutet. Publication: "Continuous Immunotypes describe human immune variation and predict various responses".  Kevin J. Kaczorowski, Karthik Shekhar, Dieudonné Nkulikiyimfura, Cornelia L. Dekker, Holden Maecker, Mark M. Davis, Arup K. Chakraborty, Petter Brodin. Proceedings of the National Academy of Sciences (PNAS), online 10 July 2017. For more information, please contact: Petter Brodin, physician, researcher Department of Medicine, Solna, Karolinska Institutet Science for Life Laboratory (SciLifeLab) Phone: +46 (0)8 524 813 96 Email: Petter.Brodin@ki.se

KI-researchers receive funding from AFA Insurance

Thu, 06/07/2017 - 14:41
Three researchers from Karolinska Institutet receive a total of SEK 9.5 million in research funding from AFA insurance, for research that will help reduce occupational injuries and long-term sickness absence. Gun Johansson at the Institute of Environmental Medicine receives SEK 2,960,000 to evaluate the effects that organisational and social measures within the workplace in the construction industry have on working conditions, health and occupational injuries. The research project runs until 2019, and the hope is to reduce levels of mental illness in the construction industry, and that the knowledge acquired will lead to fewer occupational injuries. Gunnar Bergström at the Institute of Environmental Medicine receives SEK 4,130,000 to study the link between sickness presenteeism (working while sick) and sickness absence, various types of illnesses, future sickness and decreased productivity. The research project runs until 2019 and is expected to increase knowledge about the relationship between the ability to work/illness, the effects of sickness presenteeism on health and productivity and the positive effects of sickness presenteeism when returning to adapted work after rehabilitation.  Eva Skillgate at the Institute of Environmental Medicine receives SEK 2,500,000 to investigate the significance of work- and lifestyle factors in respect of the risk of neck and back pain resulting in long-term disability, with or without the absence of psychological problems. The research project continues until 2020 and the expectations in terms of the results is that it will be possible to use them for preventive measures against this type of problems.

The Center for Innovative Medicine changes focus and board

Wed, 05/07/2017 - 13:50
CIMED, the Center for Innovative Medicine, is changing its focus and have a new board starting from 1 July. In addition to the new board with a greater clinical competence, CIMED is to focus more on supporting clinical research than previously. Research on chronic diseases and diseases with a heavy disease burden will also have a high priority. The CIMED board’s period of office came to an end on 30 June and acting Pro-Vice-Chancellor Anders Ekbom took the formal decision on the changes the day before. The decision was taken in consultation with County Council Director Malin Frenning and the KI- Stockholm County Council (SLL) management team. CIMED, whose objective is to find new treatments for endemic diseases, was inaugurated in 2015 and is funded primarily by SLL, but is a part of KI’s organization. SLL has now reviewed the support it provides to CIMED, which amounts to SEK 81 million annually.  In brief, the decision means that CIMED will have a more distinct focus on supporting clinical research than before. This involves providing support to both clinical research projects that are sought in competition and part-time clinical research positions, and to infrastructure that supports clinical research. The research must also be conducted in the Flemingsberg area. Research on chronic diseases and diseases with a heavy disease burden are to be prioritized. In addition to a new board, CIMED will also have a new head active within clinical research in Flemingsberg. The position will be announced and applied for in open competition.  CIMED’s new board Peter Lönnroth, professor, chair Lars I Eriksson, professor, SLL Anna Martling, professor, SLL Annika Tibell, professor, SLL Karin Dahlman-Wright, professor, KI Ulf Hedin, professor, KI Peter Stenvinkel, professor, KI

Major Vinnova and SRC grant for a new cell- and gene therapy centre

Wed, 05/07/2017 - 11:17
Karolinska Institutet and the Karolinska University Hospital will play core roles as Vinnova and the Swedish Research Council (SRC) grant SEK 48 million to the up building of a centre for development of advanced medical products within cell and gene therapies.  The centre, to be known as the Centre for Advanced Medical Products (CAMP), will be led by Pontus Blomberg, acting head of Karolinska Cell Therapy Centre at Karolinska University Hospital and associated professor at the Department of Laboratory Medicine at KI. Matti Sällberg, Professor and head of the Department of Laboratory Medicine, will be a member of the centre’s board. “The investment in CAMP is very gratifying and of great strategic national importance”, says Pontus Blomberg. The areas of cell and gene therapies are gaining ground fast, and products based on cells and genes can already be found as approved drugs. Intensive research is conducted in both Swedish academia and industry to develop the areas further. The grant will support these efforts and the objective is for the centre to be an internationally recognized player in the development of new treatments, and to contribute to national industrial growth within the field. CAMP will have a broad national base with collaborating parties from academia, research institutes, the health and medical care sector, the pharmaceutical industry and bioengineering companies.

AI analyses X-rays as well as doctors

Tue, 04/07/2017 - 11:36
Many jobs, medical and otherwise, might one day be performed using artificial intelligence. According to a new study in Acta Orthopaedica by researchers at Karolinska Institutet in collaboration with the Royal Institute of Technology and Danderyd Hospital in Sweden, self-learning programmes can already find fractures with the same accuracy as orthopaedists. Assessing radiographs requires a great deal of expertise and time, with the results very much depending on the doctor. However, artificial intelligence (AI) can simplify and standardise the work considerably, according to Max Gordon, assistant consultant in orthopaedics at Danderyd Hospital and researcher at Karolinska Institutet in Sweden, who has now published a study on how radiographs can be read using computers trained in fracture recognition. “Our study shows that AI networks can make assessments on a par with human specialists, and we hope that we’ll be able to achieve even better results with high-res X-ray images,” says Dr Gordon. Analysis of 256,000 images AI-facilitated image analysis had its major breakthrough in 2012, when the algorithm that astounded the computer world was compared to a human three-times worse at recognising objects in pictures from the internet. In only three years, it was at human level and by 2016 it was twice as good. This made Dr Gordon think about how the technique could be used in the fields of orthopaedics and radiograph analysis. In the present study, the researchers had existing AI image-recognition algorithms go through a total of 256,000 radiographs of hands, wrists and ankles from the Danderyd Hospital archives. The computer was trained how to identify fractures in two thirds of the radiographs under the guidance of the researchers and then was left to independently analyse the remaining images, which were thus completely new to the AI programme. Two consultants simultaneously analysed the same radiographs. The team found that the computer and the doctors made equally accurate analyses given the same image resolution, both finding the presence of a fracture in over 80 per cent of the cases. Many new opportunities The AI programme, which is inspired by the learning processes of the human brain, has the potential to be even better at its job if it has access to greater amounts of data. The researchers have therefore begun a follow-up study based on Danderyd Hospital’s entire orthopaedic archive of over a million high-resolution radiographs. “AI can lead to a more uniform classification and a common standard in radiograph analysis,” says Dr Gordon. “If we can go back to our digital archives, we’ll also be able to do extensive research on survival, the development of disease and work capacity – studies that have been impossible to do owing to the amount of data to process.” Publication “Artificial intelligence for analyzing orthopedic trauma radiographs: Deep learning algorithms - are they on par with humans for diagnosing fractures?” Jakub Olczak, Niklas Fahlberg, Atsuto Maki, Ali Sharif Razavian, Anthony Jilert, André Stark, Olof Sköldenberg, Max Gordon Acta Orthopaedica, 3 July 2017

Erik K Fernström prize awarded to cancer researcher Óscar Fernandez-Capetillo

Fri, 30/06/2017 - 08:47
Óscar Fernandez-Capetillo, professor of cancer therapy at the Department of Medical Biochemistry and Biophysics has been awarded the prize for his pioneering research on how DNA damage can lead to cancer and ageing. Óscar Fernandez-Capetillo researches replicative stress and replicative damage to DNA – in other words, the irregularities that occur when DNA copies itself during cell division. Such damage causes both ageing and cancer. Fernandez-Capetillo’s research interest lies in what causes this replicative stress and how cells discover and repair the resulting damage, a process in which the enzyme ATR kinase plays a key role. He has shown, for instance, that replicative stress accelerates ageing in mammals, and that ATR-blockers are a future cancer drug candidate. His group at Karolinska Institutet is also working on developing a treatment for amyotrophic lateral sclerosis (ALS). Óscar Fernandez-Capetillo was born in 1974. He was made professor of cancer therapy at KI on 1 January 2015. The Erik K Fernström prize The Eric K. Fernström Foundation was established in 1978 and annually awards a Nordic prize and six prizes to young and particularly promising researchers who have made outstanding contributions to medical science. Each medical faculty of the country elects its prize-winner. 

Review on suspected scientific misconduct

Thu, 29/06/2017 - 17:51
The Expert Group on Scientific Misconduct at the Central Ethical Review Board of the Swedish Research Council has handed in its review to KI on the case of suspected scientific misconduct regarding the scientifc study "Infusion of amniocytes from extraembryonic membranes and similar mesenchymal stem cells in cases of tissue damage, haemorrhage and/or graft-versus-host disease.". The study was referred to the Central Ethical Review Board last spring by acting Vice-Chancellor Karin Dahlman-Wright as she made the decision to initiate an investigationi on the case. Following the review the case will be further processed before reaching its final decision by KI's Vice-Chancellor, probably during ths fall.

Test identifies breast cancer patients with very low risk of death

Thu, 29/06/2017 - 17:30
A molecular test can identify which patients will have a very low risk of death from breast cancer up to 20 years after diagnosis, according to a new clinical study by researchers at Karolinska Institutet and University of California, San Francisco (UCSF). The results are published in JAMA Oncology. Since the introduction of screening, more breast cancer tumours with indolent, low-risk behaviour are detected. Better tools to identify such tumours are therefore needed to avoid overtreatment. Testing the expression of 70 genes In the new study, researchers sought to determine whether a 70-gene test with an ultralow risk threshold could accurately and reliably identify tumours with indolent behaviour to assess the risk of fatal breast cancer up to 20 years after diagnosis. The study was run in collaboration with the Stockholm breast cancer study group and the Stockholm tamoxifen (STO-3) trial. The new analysis included postmenopausal breast cancer patients enrolled in the STO-3 trial from 1976 until 1990, randomised to receive tamoxifen treatment versus no systemic therapy. “We concluded that the ultralow risk threshold identifies patients at very low long-term risk of dying from breast cancer,” says Senior author Linda Lindström, researcher at the Department of Biosciences and Nutrition at Karolinska Institutet. “Since breast cancer is such a diverse disease, it is important to be able to identify patients at very low long-term risk.” Important step towards personalised care The test classified 15 per cent of the patients as very low risk patients, showing that such tumours are an inherent part of the spectrum of breast cancers. Women with ultralow risk tumours had an excellent prognosis, whether or not they received tamoxifen. “This is an important step forward for personalising care for women with breast cancer,” says Laura Esserman, breast cancer specialist and professor at UCSF. “We can now test small node-negative breast cancers, and if they are in the ultralow risk category, we can tell women that they are highly unlikely to die of their cancers and do not need aggressive treatment.” The study was financed by California Breast Cancer Research Program BCRP, the Swedish Research Council, the Swedish Research Council for Health, Working life and Welfare (FORTE) and the Gösta Milton Donation Fund. Publication “Use of Molecular Tools to Identify Patients With Indolent Breast Cancers With Ultralow Risk Over 2 Decades”. Laura Esserman, Christina Yau, Carlie Thompson, Laura van 't Veer, Alexander Borowsky, Katherine Hoadley, Nicholas Tobin, Bo Nordenskjöld, Tommy Fornander, Olle Stål, Christopher Benz, and Linda S. Lindström JAMA Oncology, online 29 June 2017. doi:10.1001/jamaoncol.2017.1261

Lennart Nilsson Award is awarded to Xiaowei Zhuang

Thu, 29/06/2017 - 14:50
Xiaowei Zhuang is the recipient of the 2017 Lennart Nilsson Award for making breakthrough discoveries in the beautiful world of cell biology, literally making the invisible visible, with the STORM technique that was developed in her laboratory. Xiaowei Zhuang is the David B. Arnold Professor of Science at Harvard University and a Howard Hughes Medical Institute Investigator. In 2006, she pioneered a method that would go on to revolutionize the world of fluorescence microscopy. She developed a single-molecule-based super-resolution light microscopy method called “Stochastic Optical Reconstruction Microscopy” or STORM. It overcame the diffraction limit and extended the spatial resolution of light microscopy by an order of magnitude to a few tens of nanometers. The resolution of STORM was further extended by Xiaowei Zhuang's laboratory to a few nanometers, nearly 100 times higher than conventional diffraction-limited light microscopy. Xiaowei Zhuang has since been using STORM to illuminate the beautiful and small world of biology in the most unexpected ways. Motivation Super-resolution light microscopy techniques have revolutionized the life sciences. With the STORM technique that was developed in Dr Xiaowei Zhuang’s laboratory, she has made breakthrough discoveries in the beautiful world of cell biology, literally making the invisible visible. Her images represent a unique combination of technical mastery, frontline science, and visual esthetics, fitting perfectly in the tradition of Lennart Nilsson. About the Lennart Nilsson Award The Lennart Nilsson Award Foundation was established in 1998 in recognition of the world-renowned Swedish photographer Lennart Nilsson and his extraordinary body of work. The main aim is to promote education, training and research within the medical, biological and engineering sciences through the use of images. This is achieved through the Lennart Nilsson Award, an international award bestowed annually upon an individual in recognition of outstanding contributions within the realm of scientific photography.

2017 Pedagogical Prize awarded to Ewa Ehrenborg

Thu, 29/06/2017 - 13:31
Karolinska Institutet’s Pedagogical Prize for 2017 goes to Ewa Ehrenborg, professor of molecular cardiovascular medicine at the Department of Medicine in Solna in recognition of her contributions to interprofessional learning and student-activating research-based education. “Thanks to her pedagogical leadership skills, Ewa Ehrenborg has made a unique contribution to the quality of the clinical placement elements of our programmes,” says prize committee chair and dean of higher education Annika Östman Wernerson. “She is a source of inspiration and an example to both teachers and students.” With her innovative approach to teaching and learning, Professor Ehrenborg has helped to develop a form of student-activating teaching that integrates the latest research and peer learning in novel and imaginative ways. She is also something of a pioneer in developing interprofessional learning between different student groups at all academic levels. “I’m delighted and a little taken aback, as I didn’t even know I’d been nominated this year,” she says. Professor Ehrenborg has been involved in KI’s biomedicine programme for many years as a teacher, course director and member of the programme committee. She is also the director of the Centre for Clinical Education (CKU-KI) and is the coordinator for teaching capacity issues for the Board of Higher Education. “This prize is for all the people around me, both the ones I work with at KI and our partners on the outside, such as from Stockholm County Council and other universities,” she says. “Without them, everything we’ve achieved would not have been possible.” The 2017 Pedagogical Prize will be officially awarded at KI’s installation ceremony, which is to be held in the Erling Persson room, Aula Medica, on 12 October 2017.   Click here for more information about KI’s Pedagogical Prize

Acupuncture does not increase fertility in women with PCOS

Tue, 27/06/2017 - 17:05
Acupuncture has no effect on involuntary childlessness caused by polycystic ovary syndrome (PCOS), the most effective treatment for PCOS being the drug chlomiphene, a joint international study conducted at Heilongjiang University of Chinese Medicine, China, reports. The study, which involved the participation of researchers at Karolinska Institutet, is published in JAMA. Women with polycystic ovary syndrome (PCOS) have high levels of male sex hormone in their blood, causing irregular ovulation and difficulties conceiving. Earlier studies have shown that acupuncture reduces high levels of male sex hormone and produces more regular ovulation. A new study conducted by an international team of researchers has examined whether acupuncture also increases the number of pregnancies and the number of babies born to women with PCOS who are trying to become pregnant. Their aim was to study if acupuncture can be used as an alternative to chlomiphene stimulation, a treatment that while effective also produces adverse reactions. 1,000 women in a clinical trial The study was carried out at Heilongjiang University of Chinese Medicine by researchers from China, the USA, Hong Kong and Sweden in 2012–2015 and involved 27 hospitals. 1,000 women were divided into four groups, two of which received active acupuncture treatment in combination with either chlomiphene stimulation or placebo, the other two receiving a control treatment involving fewer needles inserted superficially without active stimulation, again with either chlomiphene stimulation or placebo. Few negative side-effects The results show that acupuncture is not an effective infertility treatment for women with PCOS who are trying to become pregnant, nor did it have any impact on chlomiphene stimulation. “This is important information, as many women want to use acupuncture to become pregnant,” says Elisabet Stener-Victorin, docent and researcher at Karolinska Institutet’s Department of Physiology and Pharmacology and former visiting professor at Heilongjiang University of Chinese Medicine. “If you have PCOS and want to become pregnant, then drug treatment is the most effective way forward. But for women who don’t wish to become pregnant yet but who have irregular ovulation and other symptoms related to high levels of male sex hormone, acupuncture can be used to relieve the symptoms as the method has no negative side-effects.” Publication ”Effect of Acupuncture and Clomiphene in Chinese Women With Polycystic Ovary Syndrome – A Randomized Clinical Trial” Xiao-Ke Wu, Elisabet Stener-Victorin, Hong-Ying Kuang, Hong-Li Ma, Jing-Shu Gao, Liang-Zhen Xie, Li-Hui Hou, Zhen-Xing Hu, Xiao-Guang Shao, Jun Ge, Jin-Feng Zhang, Hui-Ying Xue, Xiao-Feng Xu, Rui-Ning Liang, Hong-Xia Ma, Hong-Wei Yang, Wei-Li Li, Dong-Mei Huang, Yun Sun, Cui-Fang Hao, Shao-Min Du, Zheng-Wang Yang, Xin Wang, Ying Yan, Xiu-Hua Chen, Ping Fu, Cai-Fei Ding, Ya-Qin Gao, Zhong-Ming Zhou, Chi Chiu Wang, Tai-Xiang Wu, Jian-Ping Liu, Ernest HY Ng, Richard S. Legro, Heping Zhang for PCOSAct Study Group JAMA, online 27 June 2017

SEK 138 million in grants to systems biology research

Mon, 26/06/2017 - 14:44
The Swedish Foundation for Strategic Research, SSF, has decided to give KI four grants of a total of SEK 138 million in a call within systems biology research. This is a multidisciplinary grant which requires collaboration between biologists, clinicians, mathematicians, computer scientists, engineers, physicists, chemists and others.  Projects are funded with SEK 29-35 million during a five-year period (2017-2021). Researchers/projects at Karolinska Institutet receiving grants Jonas Frisén – Nervcells Development and Networking in the Adult Brain (KI together with KTH and SciLifeLab) Olli Kallioniemi – Precision medicine for optimization of therapies in AML Sten Linnarsson – Cellular reprogramming for stem cell therapy Staffan Strömblad – Microbased system biologic analysis of cell migration (KI together with Uppsala and Lund University) In addition, KI is part of a project concerning new treatment strategies for brain cancer led by Uppsala University.

The presence of the protein KIF1Bβ can play a central role for the outcome of a neuroblastoma diagnosis

Thu, 22/06/2017 - 12:14
A high percentage of KIF1Bβ means a greater chance of the tumour spontaneously regressing and disappearing. These are the results of a study by Karolinska Institutet (KI) and the Ludwig Institute for Cancer Research Ltd. The study is to be published in the scientific journal Genes and Development. Neuroblastoma is the third most common form of childhood cancer and causes almost 15 per cent of all cancer-related deaths in children. This high mortality fully reflects both the aggressive nature of the disease and that it often gives rise to secondary tumours (metastases). Paradoxically enough, neuroblastoma also has the highest spontaneous regression frequency of all tumoural diseases. In the present study, the researchers showed that absence of KIF1Bβ contributes to normal neuroblasts not maturing into nerve cells and to a more immature neuroblastoma with a poorer prognosis. “Our study shows that unimpaired maturing of neuroblasts is a basic prerequisite for spontaneous regression of neuroblastoma. What is behind this regression is unknown, but our study is an important piece in the jigsaw for understanding the mechanisms that cause this phenomenon. Understanding this process in greater detail can provide clues for the development of new therapies. For example, it would be interesting to increase levels of KIF1Bβ activity to see if this facilitates, or even induces, tumour regression,” comments Susanne Schlisio, researcher at KI’s Department of Microbiology, Tumor and Cell Biology and at Ludwig Institute for Cancer Research Ltd. High gene expression of the NGF receptor Trka correlates well with good prognoses and with spontaneous regression of the tumour. Conversely, low levels of Trka, partnered with loss of the 1p36 chromosome locus and amplification of the MYCN oncogene, are associated with poor prognoses. “We have previously shown that the kinesin protein KIF1Bβ, which is present on chromosome 1p36, is a candidate tumour suppressor and that a low expression is correlated with lower survival of neuroblastoma patients,” says Schlisio. The research is being financed with funding from the Swedish Childhood Cancer Foundation, the Swedish Cancer Society, the Swedish Research Council, the Paradifference Foundation and the Gösta Fraenckel Foundation for Medical Research. Publications “Neuroblast differentiation during development and in neuroblastoma requires KIF1Bβ mediated transport of TRKA”, Stuart M. Fell, Shuijie M. Li, Karin Wallis, Anna Kock, Olga Surova, Vilma Rraklli, Carolin S. Höfig, Wenyu Li, Jens Mittag, Marie Arsenian Henriksson, Rajappa S. Kenchappa, Johan Holmberg, Per Kogner and Susanne Schlisio, Genes and Development, online 21 June, 2017/297077

Presence of protein important clue to tumour regression in neuroblastoma

Thu, 22/06/2017 - 09:35
The presence of the protein KIF1Bβ can play a central role for the outcome of a neuroblastoma diagnosis. A high percentage of KIF1Bβ means a greater chance of the tumour spontaneously regressing and disappearing. These are the results of a study by Karolinska Institutet (KI) and the Ludwig Institute for Cancer Research Ltd. The study is to be published in the scientific journal Genes and Development. Neuroblastoma is the third most common form of childhood cancer and causes almost 15 per cent of all cancer-related deaths in children. This high mortality fully reflects both the aggressive nature of the disease and that it often gives rise to secondary tumours (metastases). Paradoxically enough, neuroblastoma also has the highest spontaneous regression frequency of all tumoural diseases. In the present study, the researchers showed that absence of KIF1Bβ contributes to normal neuroblasts not maturing into nerve cells and to a more immature neuroblastoma with a poorer prognosis. “Our study shows that unimpaired maturing of neuroblasts is a basic prerequisite for spontaneous regression of neuroblastoma. What is behind this regression is unknown, but our study is an important piece in the jigsaw for understanding the mechanisms that cause this phenomenon. Understanding this process in greater detail can provide clues for the development of new therapies. For example, it would be interesting to increase levels of KIF1Bβ activity to see if this facilitates, or even induces, tumour regression,” comments Susanne Schlisio, researcher at KI’s Department of Microbiology, Tumor and Cell Biology and at Ludwig Institute for Cancer Research Ltd. High gene expression of the NGF receptor Trka correlates well with good prognoses and with spontaneous regression of the tumour. Conversely, low levels of Trka, partnered with loss of the 1p36 chromosome locus and amplification of the MYCN oncogene, are associated with poor prognoses. “We have previously shown that the kinesin protein KIF1Bβ, which is present on chromosome 1p36, is a candidate tumour suppressor and that a low expression is correlated with lower survival of neuroblastoma patients,” says Schlisio. The research is being financed with funding from the Swedish Childhood Cancer Foundation, the Swedish Cancer Society, the Swedish Research Council, the Paradifference Foundation and the Gösta Fraenckel Foundation for Medical Research. Publication “Neuroblast differentiation during development and in neuroblastoma requires KIF1Bβ mediated transport of TRKA”, Stuart M. Fell, Shuijie M. Li, Karin Wallis, Anna Kock, Olga Surova, Vilma Rraklli, Carolin S. Höfig, Wenyu Li, Jens Mittag, Marie Arsenian Henriksson, Rajappa S. Kenchappa, Johan Holmberg, Per Kogner and Susanne Schlisio, Genes and Development, online 21 June, 2017/29707

Review on suspected scientific misconduct

Mon, 19/06/2017 - 23:01
The Expert Group on Scientific Misconduct at the Central Ethical Review Board of the Swedish Research Council has handed in its review to KI on the case of suspected scientific misconduct regarding the scientifc article "Autologous Peripheral Blood Mononuclear Cells as Treatment in Refractory Acute Respiratory Distress Syndrome", published in Respiration in 2015. The article was referred to the Central Ethical Review Board last autumn by acting Vice-Chancellor Karin Dahlman-Wright as she made the decision to initiate an investigationi on the case. Following the review the case will be further processed before reaching its final decision by KI's Vice-Chancellor, the date for this is not yet set.  

Pages